The world’s most advanced cancer specialists are gathering in Washington DC to discuss what to do about a deadly virus.
Here’s what you need to know.
Gemini, the German company that made the vaccine, has been pushing the idea that it has developed a vaccine that can stop people from contracting cancer.
The vaccine is being tested in humans in Germany, but it’s being developed further.
Gemini’s vaccine is called the Gliadin.
It is a single shot that delivers a drug to a specific spot on the body, so that the immune system can recognise it.
Researchers at Duke University and the University of Colorado, Boulder are testing it in a study to see whether the vaccine can protect against cancerous tumours in mice.
The Gliadin is being developed by a group of German researchers led by Professor Hans-Joachim Kretschmann from the National Institute for Cancer Research (NICR) and Dr Markus Weisburd from the German Cancer Research Centre.
They are collaborating on the study in collaboration with the American Cancer Society.
The study is funded by the National Institutes of Health, the National Science Foundation, the Howard Hughes Medical Institute and the US National Cancer Institute.
Kretschman, the head of the NICR vaccine development group, said that the Glisadin vaccine had already been tested in mice, and was a “powerful first step”.
“The vaccine’s ability to prevent the virus from reproducing and spreading in the body is key to its efficacy,” he said.
“The Glisidin vaccine is a unique approach that allows for a broad range of human cancers to be effectively targeted against.”
Researchers from Duke University, the University at Buffalo and the U.S. National Institutes at Cancer have already shown that the vaccine works in mice against two types of cancer: glioblastoma (also known as non-small cell lung cancer) and melanoma.
The researchers hope to make a larger trial of the vaccine in humans and mice.
Kretschan said that, in the future, the Glispidin could also be used to target certain types of cancers, including melanoma, pancreatic cancer and brain tumours.
Dr Weisburg said the Glistimax vaccine was “extremely exciting”, but it was still too early to say whether it would be able to stop cancerous cells from forming.
“We are now starting to understand the mechanisms involved,” he told the BBC.
“In our next phase, we will try to use it to treat cancers in people who are on immunosuppressive drugs.”
He said the vaccine could be used for people with multiple cancers, who could be offered the vaccine for free.
“You can offer it for free for people who have cancer,” he added.
“And then you can give it to people who don’t have cancer.”
Dr Kretsche, from Duke, said the team was also looking at developing other vaccines for the tumours of the lung, breast and colon.
“This is something that we’re exploring now,” he explained.
“I would be very surprised if it didn’t become very practical to develop these vaccines for other cancers.”
Dr Weissburd, who also works at the NICRI, said he hoped the vaccine would be used by doctors to treat people with other types of tumours such as breast and prostate.
“It’s very important that this vaccine is used for the people with the most serious diseases,” he agreed.
In the US, researchers are trying to find a way to develop a vaccine for the human lung.
They are working with the National Cancer Society, the World Health Organization, the American Lung Association and the National Society for Biological Therapy (NSBT).
The NBSB, the International Society for Cancer Vaccines, has released an online guide, which will help people make an informed choice about the Gligimax.